Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Shares Outstanding (Diluted Average) (2022 - 2025)

Indivior Pharmaceuticals has reported Shares Outstanding (Diluted Average) over the past 4 years, most recently at $128.0 million for Q4 2025.

  • Quarterly results put Shares Outstanding (Diluted Average) at $128.0 million for Q4 2025, down 3.76% from a year ago — trailing twelve months through Dec 2025 was $128.0 million (down 3.76% YoY), and the annual figure for FY2025 was $128.0 million, down 3.76%.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $128.0 million at Indivior Pharmaceuticals, up from $127.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Diluted Average) for INDV hit a ceiling of $139.0 million in Q4 2022 and a floor of $125.0 million in Q1 2025.
  • Median Shares Outstanding (Diluted Average) over the past 4 years was $133.0 million (2024), compared with a mean of $132.0 million.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): dropped 1.44% in 2023 and later dropped 8.76% in 2025.
  • Indivior Pharmaceuticals' Shares Outstanding (Diluted Average) stood at $139.0 million in 2022, then dropped by 1.44% to $137.0 million in 2023, then decreased by 2.92% to $133.0 million in 2024, then fell by 3.76% to $128.0 million in 2025.
  • The last three reported values for Shares Outstanding (Diluted Average) were $128.0 million (Q4 2025), $127.0 million (Q3 2025), and $126.0 million (Q2 2025) per Business Quant data.